Thus, cyclin E1/CDK2 activation coupled with tumor suppressor FBW7 loss can promote CIN and tumor progression through reducing CENP-A’s centromeric localization, leading to centromere dysfunction (Figure 5A). The gene discussed is CENPA; the disease is neoplasm.